Increasing Predominance of Breast Cancer as well as the Burgeoning Accessibility of Progressive Technological and Treatment Alternatives are Fueling the Growth of the Predictive Breast Cancer Gene Testing Market during the Forecast Period 2023-2028

The Predictive Breast Cancer Gene Testing Market size is estimated to reach $2.4 billion by 2028, growing at a CAGR of 11.5% during the forecast period 2023-2028. The growth of the Predictive Breast Cancer Gene Testing Market is greatly fueled by the increasing predominance of breast cancer as well as the burgeoning accessibility of progressive technologies and treatment alternatives in Predictive Breast Cancer Gene Testing. As per World Health Organization (WHO), in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 demises worldwide. North America dominated the Predictive Breast Cancer Gene Testing market with a 38% share of the overall market in 2022. As part of precision medicine, technological effect on breast cancer diagnosis, treatment and decision-making has been examined and this is fueling the growth of the North America Predictive Breast Cancer Gene Testing industry. This helps contribute to the Predictive Breast Cancer Gene Testing industry outlook. On the basis of gene type, the Predictive Breast Cancer Gene Testing Market is segmented into High Penetrant Genes, Intermediate Penetrant Genes and Low Penetrant Genes.

Predictive Breast Cancer Gene Testing Market Growth Drivers:

• Surging Investigations on the Genetics of Breast Cancer Involving High Penetrant Genes:

At least eight candidate breast cancer susceptibility genes have been recognized. Mutations in BRCA1, BRCA2, p53 and the Cowden disease gene are comparatively infrequent, are highly penetrant and generate striking familial clusters of breast cancer. BRCA1 and BRCA2 are the most critical of these, being responsible for a supposed 80% of hereditary breast cancer and 5 to 6% of all breast cancers. Predictive genetic testing for breast cancer hazards is underway. Oncologists and primary-care physicians need to become familiar with these genetic ailments and the issues encompassing predictive testing to make suitable management decisions regarding women thought to bear a high genetic risk of breast cancer. The surging investigations on the genetics of breast cancer involving high penetrant genes are therefore driving the growth of the Predictive Breast Cancer Gene Testing Market.

• Extensive Efforts on Comprehending the Clinical Implications of Low Penetrant Genes:

Numerous breast cancer genes are presently categorized as limited-evidence genes by the National Comprehensive Cancer Network (NCCN). The evolving management for these genes stresses the clinicians' requirement for evidence-based comprehension of low penetrant breast cancer genes and their conclusions for patient care. Four intermediate penetrant genes related to breast cancer have been recognized through mutational screening of candidate genes: CHEK2, ATM, BRIP1 and PALB2. Mutations in intermediate penetrant genes are rare and confer a comparative risk of breast cancer of two to four. The extensive efforts in comprehending the clinical implications of low penetrant genes are therefore propelling the growth of the Predictive Breast Cancer Gene Testing Industry, thereby contributing to the Predictive Breast Cancer Gene Testing Industry Outlook.

Product Launch:

In July 2021, Roche declared the research use only (RUO) introduction of three novel automated digital pathology algorithms, uPath Ki-67 (30-9), uPath ER (SP1) and uPath PR (1E2) image analysis for breast cancer. These are vital biomarkers for breast cancer patients.

Predictive Breast Cancer Gene Testing Market: Competitive Landscape